Braunstein, MD, PhD, FACP, and hematology/oncology fellow Olivia Main, MD, talk about their choices for a patient with ...

The Department of Veterans Affairs has started the process to designate multiple myeloma and acute and chronic leukemias as ...

MMRF Multiple Myeloma Community Connect event to be held Nov. 14 ...

Multiple myeloma is a type of cancer where plasma cells in bone marrow replicate out of control. Doctors use the acronym CRAB to diagnose myeloma by identifying four symptoms. The National Cancer ...

Multiple Myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...

Are an adult with relapsed or refractory multiple myeloma Have tried at least four previous lines of treatments for multiple myeloma, including: Immune system modulators (help boost the immune ...

Nammi Therapeutics has commenced the first in-human Phase I trial of QXL138AM by dosing the first subject for treating ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

In a real-world study involving patients with standard-risk, newly-diagnosed multiple myeloma (NDMM), there was no significant difference identified in the level of minimal residual disease (MRD) ...

The FDA has granted LBL-034 orphan drug designation for relapsed/refractory multiple myeloma treatment. LBL-034 has received ...

The CAR-T cell therapy Carvykti has been shown to be effective among patients outside the confines of a clinical trial.